Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (Iparomlimab + Tuvonralimab) with regorafenib in second-line and later advanced hepatocellular carcinoma
ChiCTR2500106875Phase 2Not yet recruiting
- Sponsor
- Huai'an First People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and regorafenib in hepatocellular carcinoma (HCC), sponsored by Huai'an First People's Hospital. Primary endpoint: Objective response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106875.